Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 58, showing 10 Applications out of 576 total, starting on record 231, ending on 240

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

231.

ECCT/17/06/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
2. KAVI Institute of Clinical Research (Nairobi City county)
 
10-10-2017 View

232.

ECCT/13/10/03  
    The Impact of Supplementation with Iron and Vitamin B12 Singly and In Combination on Nutritional Status and Morbidity Among Primary School Children.   
Principal Investigator(s)
1. Priscilla Monyangi Dr. Nyakundi
Site(s) in Kenya
Kilifi County, Ganze District.
 
02-02-2013 View

233.

ECCT/22/04/02   GO42144
    A PHASE Ia/Ib DOSE-ESCALATION AND DOSE- EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITYOF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS        
Principal Investigator(s)
1. Mansoor Noorali Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
19-08-2022 View

234.

ECCT/23/05/04   PRIORITY Trial
    Prevention of Iron Deficiency Anemia Post-delivery   
Principal Investigator(s)
1. FABIAN OMODING ESAMAI
2. PAUL OBANDA NYONGESA
Site(s) in Kenya
BUSIA COUNTY REFERRAL HOSPITAL
 
18-09-2023 View

235.

ECCT/21/09/04   Recombinant COVID-19 Vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells) for the prevention of COVID-19 in adults aged 18 years and older            
Principal Investigator(s)
1. Sylvester Kimaiyo
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (Nairobi City county)
2. Moi Teaching and Referral Hospital (Uasin Gishu county)
3. Kenya Medical Research Institute, Kilifi (Kilifi county)
 
17-09-2021 View

236.

ECCT/15/12/02   The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial
    A Multi Centre, Open label, Randomized Clinical Trial, Comparing HIV incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone Acetate, Levernogestrel (LNG) implant and Copper Intrauterine Devices (IUD).   Short Title : The Evidence for Contraceptive options and HIV Outcomes (ECHO) Trial   
Principal Investigator(s)
1. Prof Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI-RCTP Study center , Lumumba
 
11-04-2016 View

237.

ECCT/20/09/06   Schisto RDT evaluation
    A performance evaluation of a prototype rapid diagnostic test for the diagnosis of schistosomiasis   
Principal Investigator(s)
1. Sammy Njenga
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI)
 
01-12-2020 View

238.

ECCT/21/02/01   PTSD 102 TONIX
    A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime (Protocol No. TNX-CY-P308).   
Principal Investigator(s)
1. Prof. Lukoye Atwoli
Site(s) in Kenya
1. Moi Teaching and Referral Hospital/Moi University (Uasin Gishu county)
2. KEMRI Nairobi (Nairobi City county)
3. Aga Khan University Hospital (Nairobi City county)
 
16-06-2021 View

239.

ECCT/20/08/04   LOW DOSE RADIATION THERAPY
    A pilot phase Ib/II study of whole-lung low dose radiation therapy (LDRT) in the treatment of severe Covid 19 pneumonia patients on (or requiring) mechanical ventilatory support   
Principal Investigator(s)
1. PROF. MANSOOR SALEH
Site(s) in Kenya
Aga Khan University Hospital, Nairobi
 
11-11-2020 View

240.

ECCT/19/04/02   NADIA \"Nucleosides And Darunavir/Dolutegravir In Africa\"
    A randomised controlled trial of darunavir versus dolutegravir and tenofovir versus zidovudine in second-line antiretroviral therapy regimens for the public health approach in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
12-08-2019 View